Biomea Fusion Investor Relations Material

Biomea Fusion Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of covalent small molecule drugs. These drugs are designed to treat patients with genetically defined cancers and metabolic diseases. The company’s approach leverages covalent bonding, where a small molecule forms a permanent bond with its target protein, which may offer advantages like greater target selectivity and a more durable therapeutic response. The company is headquartered in Redwood City, California, and its shares are listed on the NASDAQ.